Rafaella Fabiana Carneiro Pereira

Rafaella Fabiana Carneiro Pereira

Auto-generated profile, based on publicly available information

Rafaella Fabiana Carneiro Pereira

Department of Biochemistry and Tissue Biology, Institute of Biology, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
DADanilo Antonini Alves
Danilo Antonini Alves
DMDaisy Machado
Daisy Machado
AMAdriana Melo
Adriana Melo
RPRafaella Fabiana Carneiro Pereira
Rafaella Fabiana Carneiro Pereira
Patricia SeverinoPatricia Severino
Patricia Severino
Marcelo LancellottiMarcelo Lancellotti
Marcelo Lancellotti
Levofloxacin is a synthetic broad-spectrum antibacterial agent for oral or intravenous administration. Chemically, levofloxacin is the levorotatory isomer (L-isomer) of racemate ofloxacin, a fluoroquinolone antibacterial agent. Quinolone derivatives rapidly and specifically inhibit the synthesis of bacterial DNA. Levofloxacin hasin vitroactivity against a broad range of aerobic and anaerobic Gram-positive and Gram-negative bacteria. However, formulation of combined poloxamers thermoregulated (as Pluronic® F127) and levofloxacin for use in multiresistant bacterial treatment were poorly described in the current literature. Thus, the aim of the present work is to characterize poloxamers for levofloxacin controlled release and their use in the treatment of multidrug bacterial resistance. Micelles were produced in colloidal dispersions, with a diameter between 5 and 100 nm, which form spontaneously from amphiphilic molecules under certain conditions as concentration and temperature. Encapsulation of levofloxacin into nanospheres showed efficiency and enhancement of antimicrobial activity againstEscherichia coli,Pseudomonas aeruginosa, andKlebsiella pneumoniaewhen compared with only levofloxacin. Furthermore, all formulations were not cytotoxic for NIH/3T3 cell lineage. In conclusion, poloxamers combined with levofloxacin have shown promising results, better than alone, decreasing the minimal inhibitory concentration of the studied bacterial multiresistance strains. In the future, this new formulation will be used after being tested in animal models in patients with resistant bacterial strains.

1 July 1993 in Virology
Verified
Journal Article
Closed access
AEAna Belen Espinoza
Ana Belen Espinoza
RPR. Pereira
R. Pereira
AMAna V. Macaya-Lizano
Ana V. Macaya-Lizano
MHMyriam Hernández
Myriam Hernández
MGM. Goulden
M. Goulden
CRCarmen Rivera
Carmen Rivera

25 July 2019 in Microbiology Resource Announcements
Verified
Journal Article
Open access
PDF file
RPRafaella F. C. Pereira
Rafaella F. C. Pereira
LMLuciana S. Mofatto
Luciana S. Mofatto
ASAna C. A. Silva
Ana C. A. Silva
DADanilo A. Alves
Danilo A. Alves
DMDaisy Machado
Daisy Machado
MLMarcelo Lancellotti
Marcelo Lancellotti
Brazilian purpuric fever is a febrile hemorrhagic pediatric disease caused by Haemophilus influenzae biogroup aegyptius , a bacterium which was formerly associated with only self-limited purulent conjunctivitis. Here, we present draft genomes of strains from five Brazilian purpuric fever cases and one conjunctivitis case.